Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective.

Détails

ID Serval
serval:BIB_B533AA4788A5
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective.
Périodique
Cancer cell
Auteur⸱e⸱s
Ramelyte E., Tastanova A., Balázs Z., Ignatova D., Turko P., Menzel U., Guenova E., Beisel C., Krauthammer M., Levesque M.P., Dummer R.
ISSN
1878-3686 (Electronic)
ISSN-L
1535-6108
Statut éditorial
Publié
Date de publication
08/03/2021
Peer-reviewed
Oui
Volume
39
Numéro
3
Pages
394-406.e4
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Talimogene laherparepvec (T-VEC) is a genetically modified herpes simplex 1 virus (HSV-1) approved for cancer therapy. We investigate its effect on the clinical, histological, single-cell transcriptomic, and immune repertoire level using repeated fine-needle aspirates (FNAs) of injected and noninjected lesions in primary cutaneous B cell lymphoma (pCBCL). Thirteen patients received intralesional T-VEC, 11 of which demonstrate tumor response in the injected lesions. Using single-cell sequencing of the FNAs, we identify the malignant population and separate three pCBCL subtypes. Twenty-four hours after the injection, we detect HSV-1 <sup>T-VEC</sup> transcripts in malignant and nonmalignant cells of the injected lesion but not of the noninjected lesion. Oncolytic virotherapy results in a rapid eradication of malignant cells. It also leads to interferon pathway activation and early influx of natural killer cells, monocytes, and dendritic cells. These events are followed by enrichment in cytotoxic T cells and a decrease of regulatory T cells in injected and noninjected lesions.
Mots-clé
T-VEC-induced innate and adaptive immunity, nonspecific cell infection, oncolytic virotherapy, primary cutaneous B cell lymphoma, single-cell RNA sequencing, single-cell immune repertoire profiling
Pubmed
Création de la notice
08/02/2021 8:47
Dernière modification de la notice
16/03/2021 6:25
Données d'usage